| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 19 | 2024 | 2206 | 3.760 |
Why?
|
| Head and Neck Neoplasms | 28 | 2024 | 2926 | 3.260 |
Why?
|
| Carcinoma, Squamous Cell | 22 | 2024 | 4049 | 1.970 |
Why?
|
| Receptors, Aryl Hydrocarbon | 4 | 2021 | 222 | 1.930 |
Why?
|
| Mouth Neoplasms | 7 | 2023 | 595 | 1.520 |
Why?
|
| Tumor Microenvironment | 12 | 2024 | 3942 | 1.080 |
Why?
|
| Receptors, Nerve Growth Factor | 3 | 2018 | 199 | 1.000 |
Why?
|
| Immunity, Innate | 4 | 2024 | 3079 | 0.980 |
Why?
|
| Chemokine CXCL10 | 1 | 2024 | 310 | 0.860 |
Why?
|
| Lymphocyte Subsets | 2 | 2021 | 313 | 0.770 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 178 | 0.680 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2022 | 287 | 0.660 |
Why?
|
| Immunotherapy | 8 | 2023 | 4746 | 0.650 |
Why?
|
| Neoplasms, Experimental | 4 | 2018 | 1227 | 0.560 |
Why?
|
| Receptor, Nerve Growth Factor | 1 | 2016 | 48 | 0.550 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2020 | 325 | 0.540 |
Why?
|
| Infant, Premature, Diseases | 1 | 2022 | 712 | 0.530 |
Why?
|
| Lymphocytes | 2 | 2021 | 2602 | 0.530 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 385 | 0.510 |
Why?
|
| Neoplastic Stem Cells | 2 | 2014 | 1351 | 0.490 |
Why?
|
| Melanoma | 8 | 2024 | 5695 | 0.490 |
Why?
|
| Cell Line, Tumor | 17 | 2024 | 17071 | 0.490 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 1138 | 0.470 |
Why?
|
| Skin Neoplasms | 9 | 2024 | 5836 | 0.450 |
Why?
|
| Microvessels | 4 | 2020 | 590 | 0.440 |
Why?
|
| Nerve Tissue Proteins | 3 | 2018 | 4399 | 0.440 |
Why?
|
| Neoplasm Invasiveness | 5 | 2018 | 3602 | 0.440 |
Why?
|
| Sentinel Lymph Node Biopsy | 3 | 2024 | 733 | 0.440 |
Why?
|
| Lymphatic System | 1 | 2015 | 250 | 0.440 |
Why?
|
| Proteoglycans | 1 | 2016 | 794 | 0.430 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2015 | 347 | 0.420 |
Why?
|
| Histones | 1 | 2023 | 2591 | 0.410 |
Why?
|
| Vasoconstriction | 4 | 2020 | 593 | 0.410 |
Why?
|
| Cell Movement | 5 | 2021 | 5196 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2020 | 9378 | 0.380 |
Why?
|
| Microcirculation | 2 | 2020 | 1282 | 0.380 |
Why?
|
| Cerebral Hemorrhage | 2 | 2022 | 2649 | 0.380 |
Why?
|
| Cell Adhesion Molecules | 1 | 2018 | 1610 | 0.380 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2021 | 1504 | 0.380 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 1105 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2824 | 0.370 |
Why?
|
| Antigens, CD | 2 | 2021 | 4025 | 0.370 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 1884 | 0.350 |
Why?
|
| Immune System | 1 | 2015 | 799 | 0.340 |
Why?
|
| Anemia, Sickle Cell | 4 | 2020 | 1063 | 0.340 |
Why?
|
| Mice | 25 | 2024 | 81839 | 0.330 |
Why?
|
| Neoplasms | 9 | 2024 | 22344 | 0.320 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2011 | 265 | 0.320 |
Why?
|
| Animals | 33 | 2024 | 168800 | 0.290 |
Why?
|
| Cerebrovascular Circulation | 4 | 2022 | 2675 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 4 | 2015 | 9237 | 0.290 |
Why?
|
| Maxillary Artery | 1 | 2007 | 18 | 0.280 |
Why?
|
| Antigens, Neoplasm | 2 | 2014 | 1996 | 0.280 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2023 | 4649 | 0.280 |
Why?
|
| Humans | 83 | 2024 | 766117 | 0.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8612 | 0.270 |
Why?
|
| Aneurysm, Infected | 1 | 2007 | 82 | 0.260 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 5503 | 0.250 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 2 | 2024 | 29 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2022 | 2570 | 0.250 |
Why?
|
| NF-kappa B | 6 | 2022 | 2495 | 0.250 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3111 | 0.250 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3233 | 0.250 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 978 | 0.240 |
Why?
|
| Thyroid Neoplasms | 4 | 2024 | 2354 | 0.230 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 18321 | 0.230 |
Why?
|
| Aneurysm, False | 1 | 2007 | 264 | 0.230 |
Why?
|
| Cell Growth Processes | 2 | 2015 | 380 | 0.220 |
Why?
|
| Organoids | 2 | 2021 | 740 | 0.220 |
Why?
|
| Cerebrovascular Disorders | 1 | 2011 | 1478 | 0.220 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2023 | 698 | 0.220 |
Why?
|
| Genes, cdc | 1 | 2023 | 113 | 0.220 |
Why?
|
| Infant, Premature | 2 | 2024 | 2121 | 0.210 |
Why?
|
| Spectrum Analysis | 2 | 2022 | 443 | 0.210 |
Why?
|
| Pandemics | 2 | 2020 | 8725 | 0.210 |
Why?
|
| Gastrointestinal Agents | 1 | 2008 | 511 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2016 | 3604 | 0.210 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2023 | 752 | 0.200 |
Why?
|
| Cell Differentiation | 4 | 2021 | 11642 | 0.200 |
Why?
|
| Sotos Syndrome | 1 | 2022 | 10 | 0.200 |
Why?
|
| Music Therapy | 1 | 2024 | 111 | 0.200 |
Why?
|
| Vascular Diseases | 2 | 2020 | 1161 | 0.190 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2021 | 66 | 0.190 |
Why?
|
| alpha-Globins | 1 | 2020 | 20 | 0.180 |
Why?
|
| Liver | 1 | 2016 | 7559 | 0.180 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2011 | 1663 | 0.180 |
Why?
|
| alpha-Thalassemia | 1 | 2020 | 53 | 0.180 |
Why?
|
| Primary Dysautonomias | 1 | 2020 | 28 | 0.180 |
Why?
|
| Interleukin-15 | 1 | 2021 | 186 | 0.180 |
Why?
|
| Fiber Optic Technology | 1 | 2022 | 290 | 0.170 |
Why?
|
| Electrons | 1 | 2021 | 264 | 0.170 |
Why?
|
| Homeodomain Proteins | 2 | 2013 | 2430 | 0.170 |
Why?
|
| Protein Engineering | 1 | 2024 | 550 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 5 | 2018 | 6215 | 0.170 |
Why?
|
| Hyperemia | 1 | 2020 | 223 | 0.160 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 277 | 0.160 |
Why?
|
| Interferon Type I | 1 | 2023 | 568 | 0.160 |
Why?
|
| Flow Cytometry | 3 | 2024 | 5881 | 0.160 |
Why?
|
| Chemokines | 1 | 2023 | 959 | 0.160 |
Why?
|
| Chemokines, CXC | 1 | 2020 | 417 | 0.160 |
Why?
|
| Lymph Nodes | 4 | 2024 | 3456 | 0.150 |
Why?
|
| Laryngectomy | 1 | 2020 | 245 | 0.150 |
Why?
|
| Cranial Nerves | 1 | 2018 | 97 | 0.150 |
Why?
|
| Infant, Newborn | 9 | 2024 | 26381 | 0.150 |
Why?
|
| Models, Immunological | 2 | 2018 | 517 | 0.140 |
Why?
|
| Cross-Over Studies | 1 | 2024 | 2108 | 0.140 |
Why?
|
| Gene Expression Profiling | 5 | 2020 | 9527 | 0.140 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2015 | 304 | 0.140 |
Why?
|
| Brain | 7 | 2024 | 27177 | 0.140 |
Why?
|
| Health Priorities | 1 | 2020 | 382 | 0.140 |
Why?
|
| Integrin alpha1 | 1 | 2016 | 13 | 0.140 |
Why?
|
| Hypoparathyroidism | 1 | 2018 | 136 | 0.140 |
Why?
|
| Arterioles | 1 | 2017 | 251 | 0.140 |
Why?
|
| Integrin alpha2 | 1 | 2016 | 39 | 0.140 |
Why?
|
| Boronic Acids | 2 | 2015 | 915 | 0.140 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 4342 | 0.130 |
Why?
|
| Vasodilation | 1 | 2020 | 969 | 0.130 |
Why?
|
| Thyroidectomy | 2 | 2021 | 912 | 0.130 |
Why?
|
| Temperature | 2 | 2020 | 2227 | 0.130 |
Why?
|
| Microscopy | 1 | 2021 | 900 | 0.130 |
Why?
|
| Luminescence | 1 | 2016 | 109 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 5336 | 0.130 |
Why?
|
| Ubiquitination | 1 | 2021 | 1000 | 0.130 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 441 | 0.130 |
Why?
|
| Dermatitis, Contact | 1 | 2016 | 134 | 0.130 |
Why?
|
| Cytokines | 6 | 2023 | 7426 | 0.130 |
Why?
|
| Carcinoma | 4 | 2016 | 2313 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2020 | 430 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 22341 | 0.130 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 615 | 0.130 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2016 | 195 | 0.120 |
Why?
|
| Beta Particles | 1 | 2015 | 51 | 0.120 |
Why?
|
| Nerve Growth Factor | 1 | 2016 | 156 | 0.120 |
Why?
|
| Zymosan | 1 | 2015 | 133 | 0.120 |
Why?
|
| Phenotype | 4 | 2024 | 16716 | 0.120 |
Why?
|
| Pyrazines | 2 | 2015 | 1204 | 0.120 |
Why?
|
| Ameloblastoma | 1 | 2015 | 42 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2024 | 1552 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.120 |
Why?
|
| Cells, Cultured | 4 | 2018 | 18967 | 0.120 |
Why?
|
| Jaw Neoplasms | 1 | 2015 | 71 | 0.120 |
Why?
|
| Peripheral Nerves | 1 | 2018 | 491 | 0.120 |
Why?
|
| Prognosis | 10 | 2024 | 29912 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 560 | 0.120 |
Why?
|
| STAT1 Transcription Factor | 1 | 2016 | 340 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2021 | 1318 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 10260 | 0.110 |
Why?
|
| Guanosine Triphosphate | 1 | 2015 | 314 | 0.110 |
Why?
|
| Ulcer | 1 | 2015 | 202 | 0.110 |
Why?
|
| Pain | 3 | 2018 | 5090 | 0.110 |
Why?
|
| RNA, Ribosomal | 1 | 2015 | 227 | 0.110 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 341 | 0.110 |
Why?
|
| RNA Interference | 3 | 2017 | 2828 | 0.110 |
Why?
|
| Computers, Handheld | 1 | 2015 | 211 | 0.110 |
Why?
|
| Female | 29 | 2024 | 396233 | 0.110 |
Why?
|
| Gestational Age | 1 | 2022 | 3616 | 0.110 |
Why?
|
| Artifacts | 1 | 2022 | 1896 | 0.110 |
Why?
|
| Oral Surgical Procedures | 1 | 2015 | 172 | 0.110 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 13635 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 565 | 0.100 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 13483 | 0.100 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2013 | 158 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2021 | 1378 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2022 | 2879 | 0.100 |
Why?
|
| Lymphatic Metastasis | 4 | 2023 | 2890 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 2 | 2022 | 1077 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2017 | 1837 | 0.100 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 2469 | 0.100 |
Why?
|
| Immunomagnetic Separation | 1 | 2012 | 78 | 0.100 |
Why?
|
| Tissue and Organ Procurement | 1 | 2020 | 988 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2021 | 2029 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1602 | 0.100 |
Why?
|
| Pharyngectomy | 1 | 2011 | 45 | 0.100 |
Why?
|
| Transcription Factors | 3 | 2021 | 12130 | 0.100 |
Why?
|
| Male | 25 | 2024 | 363935 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2020 | 2142 | 0.100 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 872 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2020 | 2502 | 0.090 |
Why?
|
| Multienzyme Complexes | 1 | 2015 | 663 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2021 | 6545 | 0.090 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 1637 | 0.090 |
Why?
|
| Genes, Viral | 1 | 2012 | 654 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 1985 | 0.090 |
Why?
|
| Electroencephalography | 2 | 2024 | 6279 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2018 | 12775 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 3424 | 0.090 |
Why?
|
| Brain Injuries | 1 | 2022 | 2062 | 0.090 |
Why?
|
| Australia | 2 | 2024 | 1260 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 4887 | 0.080 |
Why?
|
| Survival Analysis | 3 | 2017 | 10087 | 0.080 |
Why?
|
| Chromatin | 1 | 2021 | 2981 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 20700 | 0.080 |
Why?
|
| Biomimetics | 1 | 2011 | 168 | 0.080 |
Why?
|
| Electronics | 1 | 2011 | 314 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2023 | 3283 | 0.080 |
Why?
|
| Palliative Care | 2 | 2022 | 3639 | 0.080 |
Why?
|
| Receptors, IgG | 1 | 2012 | 559 | 0.080 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 615 | 0.080 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 920 | 0.080 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 996 | 0.080 |
Why?
|
| Seizures | 1 | 2022 | 2997 | 0.080 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 59515 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2020 | 2339 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2016 | 2196 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 2010 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 11200 | 0.080 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2008 | 27 | 0.080 |
Why?
|
| Prostatectomy | 1 | 2016 | 1786 | 0.080 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2008 | 47 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 1490 | 0.070 |
Why?
|
| Quality of Life | 2 | 2023 | 13468 | 0.070 |
Why?
|
| Patient Selection | 1 | 2020 | 4249 | 0.070 |
Why?
|
| Aged | 13 | 2024 | 171219 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1042 | 0.070 |
Why?
|
| Retrospective Studies | 11 | 2024 | 81565 | 0.070 |
Why?
|
| Middle Aged | 15 | 2024 | 223083 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 3928 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2022 | 4425 | 0.070 |
Why?
|
| Antibodies | 2 | 2012 | 2415 | 0.070 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 1814 | 0.070 |
Why?
|
| Mice, SCID | 1 | 2012 | 2626 | 0.070 |
Why?
|
| Adult | 17 | 2024 | 223139 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 2249 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 3733 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2015 | 8292 | 0.070 |
Why?
|
| HLA-B Antigens | 1 | 2008 | 329 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2020 | 3787 | 0.070 |
Why?
|
| Data Collection | 1 | 2015 | 3318 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 1883 | 0.060 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2005 | 44 | 0.060 |
Why?
|
| Infant | 3 | 2022 | 36427 | 0.060 |
Why?
|
| Receptors, Immunologic | 1 | 2012 | 1416 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2017 | 3561 | 0.060 |
Why?
|
| Mice, Knockout | 1 | 2021 | 14456 | 0.060 |
Why?
|
| Homeostasis | 1 | 2016 | 3338 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2011 | 1273 | 0.060 |
Why?
|
| Depression | 1 | 2024 | 8230 | 0.060 |
Why?
|
| Immune Tolerance | 2 | 2022 | 2324 | 0.060 |
Why?
|
| Signal Transduction | 5 | 2022 | 23605 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 4 | 2021 | 5784 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 2838 | 0.060 |
Why?
|
| Gene Expression | 3 | 2022 | 7582 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 2898 | 0.060 |
Why?
|
| Monitoring, Physiologic | 2 | 2022 | 1794 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 2390 | 0.060 |
Why?
|
| Glutaminase | 1 | 2023 | 31 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2016 | 4910 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 5791 | 0.050 |
Why?
|
| Autonomic Nervous System | 2 | 2019 | 705 | 0.050 |
Why?
|
| Mutagenesis, Insertional | 1 | 2005 | 663 | 0.050 |
Why?
|
| Respiratory Rate | 1 | 2024 | 179 | 0.050 |
Why?
|
| Genes, Developmental | 1 | 2022 | 38 | 0.050 |
Why?
|
| Survival Rate | 4 | 2019 | 12827 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2002 | 56 | 0.050 |
Why?
|
| Transgenes | 1 | 2005 | 1014 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2023 | 287 | 0.050 |
Why?
|
| Cross Reactions | 1 | 2024 | 825 | 0.050 |
Why?
|
| Endoscopy | 1 | 2011 | 1854 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 750 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 8525 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 36548 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 4565 | 0.050 |
Why?
|
| Music | 1 | 2024 | 248 | 0.050 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 203 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2022 | 41684 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2023 | 475 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2002 | 322 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2024 | 540 | 0.040 |
Why?
|
| Hemorheology | 1 | 2020 | 144 | 0.040 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2020 | 236 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 385 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 11906 | 0.040 |
Why?
|
| Blood Pressure | 3 | 2021 | 8532 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 671 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2021 | 4263 | 0.040 |
Why?
|
| Lymphokines | 1 | 2002 | 905 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2002 | 699 | 0.040 |
Why?
|
| Brachial Artery | 1 | 2020 | 374 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2005 | 1362 | 0.040 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 754 | 0.040 |
Why?
|
| Stroke | 1 | 2021 | 9748 | 0.040 |
Why?
|
| Intracranial Pressure | 1 | 2021 | 323 | 0.040 |
Why?
|
| United States | 3 | 2024 | 72920 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2008 | 9540 | 0.040 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2024 | 749 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2015 | 3610 | 0.040 |
Why?
|
| Mutation | 6 | 2023 | 30209 | 0.040 |
Why?
|
| Motion | 1 | 2022 | 782 | 0.040 |
Why?
|
| Hypesthesia | 1 | 2018 | 106 | 0.040 |
Why?
|
| Rats | 2 | 2012 | 23717 | 0.040 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 3360 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6506 | 0.040 |
Why?
|
| Immunity | 1 | 2023 | 1001 | 0.040 |
Why?
|
| Receptor, trkA | 1 | 2018 | 159 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 4249 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2005 | 2136 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2011 | 6254 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2017 | 317 | 0.030 |
Why?
|
| Sickle Cell Trait | 1 | 2017 | 86 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 2946 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 3594 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2021 | 1143 | 0.030 |
Why?
|
| Biophysical Phenomena | 1 | 2017 | 318 | 0.030 |
Why?
|
| Fibroblast Growth Factors | 1 | 2022 | 871 | 0.030 |
Why?
|
| Anthropometry | 1 | 2020 | 1339 | 0.030 |
Why?
|
| Head | 1 | 2022 | 926 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2018 | 15808 | 0.030 |
Why?
|
| Time Factors | 4 | 2015 | 40108 | 0.030 |
Why?
|
| Saliva | 1 | 2020 | 852 | 0.030 |
Why?
|
| Pol1 Transcription Initiation Complex Proteins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2015 | 31 | 0.030 |
Why?
|
| RNA Polymerase I | 1 | 2015 | 23 | 0.030 |
Why?
|
| Diet | 1 | 2013 | 8087 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2018 | 6840 | 0.030 |
Why?
|
| Case-Control Studies | 3 | 2017 | 22228 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 1363 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2018 | 1336 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2021 | 1168 | 0.030 |
Why?
|
| beta-Thalassemia | 1 | 2017 | 233 | 0.030 |
Why?
|
| Protein Kinase C-delta | 1 | 2015 | 115 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1588 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 544 | 0.030 |
Why?
|
| Mandibular Neoplasms | 1 | 2015 | 131 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2015 | 284 | 0.030 |
Why?
|
| Adipokines | 1 | 2016 | 308 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 21074 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 1479 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2015 | 300 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1897 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 4044 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 11094 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 812 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 856 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2015 | 738 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 1494 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1613 | 0.030 |
Why?
|
| Immunologic Surveillance | 1 | 2013 | 92 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Cell Death | 1 | 2018 | 1676 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 1750 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2015 | 349 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2002 | 2877 | 0.030 |
Why?
|
| Adolescent | 5 | 2020 | 88819 | 0.020 |
Why?
|
| Treatment Outcome | 5 | 2020 | 65219 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2020 | 10433 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2012 | 118 | 0.020 |
Why?
|
| Maxilla | 1 | 2015 | 486 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2395 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 12976 | 0.020 |
Why?
|
| RNA | 1 | 2021 | 2716 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2016 | 1259 | 0.020 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 786 | 0.020 |
Why?
|
| Genotype | 2 | 2020 | 13028 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2017 | 1307 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4247 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 1310 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8724 | 0.020 |
Why?
|
| Magnetite Nanoparticles | 1 | 2012 | 309 | 0.020 |
Why?
|
| Cell Division | 2 | 2012 | 4466 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 11035 | 0.020 |
Why?
|
| Mandible | 1 | 2015 | 746 | 0.020 |
Why?
|
| Young Adult | 4 | 2020 | 59868 | 0.020 |
Why?
|
| Comorbidity | 1 | 2024 | 10579 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 637 | 0.020 |
Why?
|
| Glucose | 1 | 2021 | 4335 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2718 | 0.020 |
Why?
|
| Radiosurgery | 1 | 2018 | 1328 | 0.020 |
Why?
|
| ras Proteins | 1 | 2014 | 1054 | 0.020 |
Why?
|
| Pyrroles | 1 | 2015 | 1120 | 0.020 |
Why?
|
| Quinazolines | 1 | 2015 | 1366 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 74857 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 3690 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 3818 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 317 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2782 | 0.020 |
Why?
|
| Proteomics | 1 | 2021 | 3907 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2020 | 24276 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 1865 | 0.020 |
Why?
|
| Prevalence | 1 | 2024 | 15827 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 15403 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5020 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2008 | 214 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2012 | 1518 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1765 | 0.020 |
Why?
|
| Receptors, NK Cell Lectin-Like | 1 | 2005 | 30 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2005 | 21 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 3238 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2005 | 121 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 14747 | 0.020 |
Why?
|
| Models, Biological | 2 | 2017 | 9445 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2022 | 7850 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2646 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 8038 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 2005 | 297 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2015 | 5300 | 0.010 |
Why?
|
| Computational Biology | 1 | 2016 | 3565 | 0.010 |
Why?
|
| Disease Management | 1 | 2015 | 2531 | 0.010 |
Why?
|
| Transcription Factor RelA | 1 | 2005 | 252 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39243 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2004 | 210 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2004 | 201 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2019 | 4527 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2004 | 1056 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2005 | 457 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 609 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7424 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5776 | 0.010 |
Why?
|
| Stomatitis | 1 | 2005 | 270 | 0.010 |
Why?
|
| Protein Binding | 1 | 2015 | 9301 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 433 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2004 | 449 | 0.010 |
Why?
|
| Doxycycline | 1 | 2004 | 348 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2844 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2005 | 592 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4521 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 812 | 0.010 |
Why?
|
| Autoantigens | 1 | 2005 | 886 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 1498 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 748 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 712 | 0.010 |
Why?
|
| Recurrence | 1 | 2012 | 8494 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14645 | 0.010 |
Why?
|
| Keratinocytes | 1 | 2004 | 861 | 0.010 |
Why?
|
| beta Catenin | 1 | 2004 | 1047 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 1644 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2004 | 1322 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 3274 | 0.010 |
Why?
|
| Cell Line | 1 | 2012 | 15546 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2005 | 2411 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 42511 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2005 | 2729 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 2091 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20137 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 3159 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 13616 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3584 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3796 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 3801 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 2849 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 5747 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 6102 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 5739 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 6961 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 2627 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 12405 | 0.010 |
Why?
|
| Child | 1 | 2020 | 80573 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 3722 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 3501 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 54812 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 5995 | 0.010 |
Why?
|
| Apoptosis | 1 | 2005 | 9508 | 0.010 |
Why?
|